EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Tegafur–Uracil Maintenance Therapy in Non-Metastatic Head and Neck Cancer: An Exploratory Systematic Review

Hsu-Lin Lee iD, Po-Huang Chen iD, Tzu-Chuan Huang, Ren-Hua Ye, Yueng-Hsiang Chu iD, Jih-Chin Lee, Hong-Jie Jhou iD, Jia-Hong Chen

Current Oncology · 20.05.2025 · 32 (5) · 286

DOI: 10.3390/curroncol32050286 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Current Oncology, online erschienen am 20.05.2025. Verfasst von Hsu-Lin Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung 411228, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Tegafur. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tegafur–uracil (UFT), an oral fluoropyrimidine developed in Asia, has been investigated as a maintenance or adjuvant therapy in various malignancies. Its use in head and neck cancers, however, remains limited to small retrospective studies, primarily from East Asia. Given the need for cost-effective maintenance strategies in resource-limited settings, we conducted an exploratory systematic review to evaluate the clinical utility of UFT in non-metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC).

Methods

We systematically searched PubMed, EMBASE, and Cochrane Library from inception through 1 May 2025 for retrospective cohort studies evaluating UFT after definitive therapy in non-metastatic HNSCC or NPC. Study selection followed PRISMA guidelines. Given the heterogeneity of included studies, we performed a structured narrative synthesis using the SWiM (Synthesis Without Meta-analysis) framework to summarize survival outcomes, treatment settings, and clinical contexts.

Results

Seven retrospective studies (four HNSCC, three NPC) involving 508 patients were included. UFT was generally administered at 300–400 mg/day for 6–12 months. Across studies, UFT use was associated with favorable disease-free and overall survival trends in high-risk subgroups, including patients with extranodal extension and persistent EBV DNA. Treatment adherence and toxicity profiles were acceptable.

Conclusions

While the evidence remains limited and heterogeneous, this review highlights recurring signals of benefit associated with UFT maintenance therapy in selected high-risk patients. Prospective trials are warranted to confirm these findings and better define a possible role of UFT in maintenance therapy in some advanced non-metastatic HNSCC and NPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckTegafurUracilHumans

Stichwörter der Autor:innen

head and neck squamous cell carcinomamaintenance therapynasopharyngeal carcinomategafur–uracil

Substanzen

TegafurUracil

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung 411228, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan.
  • Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan.
  • Department of Neurology, Changhua Christian Hospital, Changhua 500011, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University; Taipei 11031, Taiwan.

ORCID-Profile: Hsu-Lin Lee, Po-Huang Chen, Yueng-Hsiang Chu, Hong-Jie Jhou

Zitieren

APA

Lee, H. L., Chen, P. H., Huang, T. C., Ye, R. H., Chu, Y. H., Lee, J. C., Jhou, H. J., & Chen, J. H. (2025). Tegafur–Uracil Maintenance Therapy in Non-Metastatic Head and Neck Cancer: An Exploratory Systematic Review. Current Oncology, 32(5), 286. https://doi.org/10.3390/curroncol32050286

Vancouver

Lee HL, Chen PH, Huang TC, Ye RH, Chu YH, Lee JC, et al. Tegafur–Uracil Maintenance Therapy in Non-Metastatic Head and Neck Cancer: An Exploratory Systematic Review. Current Oncology. 2025;32(5):286. doi:10.3390/curroncol32050286

BibTeX
@article{Lee2025,
  author = {Lee, Hsu-Lin and Chen, Po-Huang and Huang, Tzu-Chuan and Ye, Ren-Hua and Chu, Yueng-Hsiang and Lee, Jih-Chin and Jhou, Hong-Jie and Chen, Jia-Hong},
  title = {Tegafur–Uracil Maintenance Therapy in Non-Metastatic Head and Neck Cancer: An Exploratory Systematic Review},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {5},
  pages = {286},
  doi = {10.3390/curroncol32050286}
}
Kostenlos starten →